MedPath

Safety and Efficacy of Two Vaginal Products Versus Placebo in Patients With Vaginal Discomfort

Phase 2
Completed
Conditions
Vulvodynia
Interventions
Drug: placebo
Drug: Lidocaine/Diphenhydramine
Registration Number
NCT00590590
Lead Sponsor
Lumara Health, Inc.
Brief Summary

This study will evaluate the efficacy and safety of two vaginal products compared with that of placebo to determine if the two products are better than placebo in the relief of vaginal discomfort.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
105
Inclusion Criteria
  • Patients must have sought doctor's care for this condition.
  • Patients must be having menstrual cycles.
Exclusion Criteria
  • Patients must not have any vaginal infections.
  • Patients must not be pregnant or nursing.
  • Must not be receiving any other medicinal therapies or any medications that would interfere with the outcome of the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
3 (Placebo)placebo-
1 (Lidocaine)lidocaine-
2 (Lidocaine/Diphenhydramine)Lidocaine/Diphenhydramine-
Primary Outcome Measures
NameTimeMethod
Mean Marinoff Dyspareunia Scale Score (MDSS) at End of Treatment (12 Weeks)12 weeks

The MDSS consists of a participant rating of their dyspareunia (painful sexual intercourse) on a 0- to 3-point scale. Each numerical value on the scale coincides with a level of pain experienced during sexual intercourse; 0 = no dyspareunia (no pain with intercourse) and 3 = completely prevents intercourse

Secondary Outcome Measures
NameTimeMethod
Change From Baseline in Marinoff Dyspareunia Scale Score at End of Treatment (12 Weeks)Baseline -12 Weeks

0-3 scale with 0=no dyspareunia and 3= completely prevents intercourse

Change From Baseline in Overall Vulvar Vestibulitis Syndrome (VVS)-Related Discomfort Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Discomfort and 100 = Most Severe Discomfort]12 Weeks
Change From Baseline in Overall Intercourse-Related Pain Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Pain and 100 = Most Severe Pain]12 weeks
Change From Baseline in Overall Vulvar Vestibulitis Symptoms Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Symptoms and 100 = As Bad as They Can be]12 Weeks
Change From Baseline in Tenderness (on a 0- to 3-point Scale) on Palpation at End of Treatment (12 Weeks) [Scale Rates the Severity of Pain; 0 =Absent and 3 = Severe]12 Weeks

Trial Locations

Locations (48)

Advanced Clinical Research

🇺🇸

Medford, Oregon, United States

Lehigh Valley Health Network

🇺🇸

Allentown, Pennsylvania, United States

Woman's Hospital of Texas

🇺🇸

Houston, Texas, United States

Royal Health Care Centre

🇨🇦

Toronto, Ontario, Canada

Precision Trials LLC

🇺🇸

Phoenix, Arizona, United States

Salt Lake Research

🇺🇸

Salt Lake City, Utah, United States

Stephen Kaye, MD

🇨🇦

North Vancouver, British Columbia, Canada

Gain Medical Centre

🇨🇦

Coquitlam, British Columbia, Canada

Southeastern Clinical Research

🇺🇸

Chattanooga, Tennessee, United States

Women's Care Center, PLC

🇺🇸

Memphis, Tennessee, United States

Gynecology and Obstetrics, P.C.

🇺🇸

Memphis, Tennessee, United States

Atlanta North Gynecology, PC

🇺🇸

Roswell, Georgia, United States

Common Wealth Medical Clinic

🇨🇦

Mt. Pearl, Newfoundland and Labrador, Canada

Lyndhurst Clinical Research

🇺🇸

Winston Salem, North Carolina, United States

Montgomery Women's Health Associates, P.C.

🇺🇸

Montgomery, Alabama, United States

Advanced Clinical Concepts

🇺🇸

West Reading, Pennsylvania, United States

Women's Medical Research Group, LLC

🇺🇸

Clearwater, Florida, United States

Searcy Medical Center

🇺🇸

Searcy, Arkansas, United States

Innovative Research of W. Florida

🇺🇸

Largo, Florida, United States

Eastern Carolina Womens Center

🇺🇸

New Bern, North Carolina, United States

Rosemark Women Care Specialists

🇺🇸

Idaho Falls, Idaho, United States

Comprehensive Clinical Trials, LLC

🇺🇸

West Palm Beach, Florida, United States

Taylor Associates/Gynecology

🇺🇸

Farmington, Connecticut, United States

Atlanta Women's Research Institute, Inc.

🇺🇸

Atlanta, Georgia, United States

Star W. Research

🇺🇸

Chandler, Arizona, United States

Clinical Research of Tampa Bay

🇺🇸

Hudson, Florida, United States

Tampa Bay Women's Healthcare Alliance, LLP

🇺🇸

Tampa, Florida, United States

Bexar Clinical Trials

🇺🇸

Irving, Texas, United States

The Jackson Clinic, PA

🇺🇸

Jackson, Tennessee, United States

San Diego Clinical Research Center

🇺🇸

San Diego, California, United States

The Ottawa Hospital-Soundcare Medical Centre

🇨🇦

Ottawa, Ontario, Canada

Universal Biopharma Research Institute, Inc.

🇺🇸

Dinuba, California, United States

HWC Women's Research Center

🇺🇸

Miamisburg, Ohio, United States

Red Rocks OB/GYN

🇺🇸

Lakewood, Colorado, United States

Womans Clinic

🇺🇸

Boise, Idaho, United States

Northern Indiana Womens Health Research

🇺🇸

South Bend, Indiana, United States

Boro Park ObGyn

🇺🇸

Brooklyn, New York, United States

Women's Health Practice, LLC

🇺🇸

Champaign, Illinois, United States

Women's Health Care Specialists, PC

🇺🇸

Paw Paw, Florida, United States

Female Pelvic Medicine and Urogynecology

🇺🇸

Grand Rapids, Michigan, United States

Holzer Clinic

🇺🇸

Gallipolis, Ohio, United States

Winston-Salem Woman Care, PA

🇺🇸

Winston-Salem, North Carolina, United States

Windsor Metropolitan Hospital

🇨🇦

Windsor, Ontario, Canada

Hillcrest Clinical Research, LLC

🇺🇸

Simpsonville, South Carolina, United States

Advanced Research Associates

🇺🇸

Corpus Christi, Texas, United States

Salt Lake Women's Center

🇺🇸

Sandy, Utah, United States

Professional Quality Research/Women Partners

🇺🇸

Austin, Texas, United States

Southern Healthcare Centre

🇨🇦

White Rock, British Columbia, Canada

© Copyright 2025. All Rights Reserved by MedPath